Ductal Carcinoma in Situ

Ibex obtains CE Mark for Galen Breast software

By LabPulse.com staff writers

Galen Breast uses artificial intelligence (AI) and machine learning and was trained on hundreds of thousands of image samples, scanned from biopsy slides digitized using digital pathology, according to the company.

May 25, 2021

Prelude highlights ASTRO data on breast cancer risk test

By LabPulse.com staff writers

The study included nearly 1,800 women diagnosed with ductal carcinoma in situ (DCIS) and classified as low risk by radiation oncology/toxicity grading-like criteria for recurrence of DCIS or progression to invasive breast cancer. The DCISionRT assay reclassified almost half of these patients to elevated risk, which suggests numerous patients would have been undertreated with surgery alone.

October 29, 2020

Study urges broader genetic testing of breast cancer patients

By Kate Madden Yee

The National Comprehensive Cancer Network's (NCCN) current guidelines for genetic testing recommend it for women younger than 46 who are diagnosed with breast cancer, regardless of family history or cancer subtype. But expanding the age range for genetic testing would help identify more women with mutations that make them vulnerable, concluded first author Dr. Siddhartha Yadav, a hematology-oncology fellow at the Mayo Clinic in Rochester, MN, and colleagues.

March 3, 2020

CAP, ASCO taking comments on guidelines for breast cancer receptor testing

By Brian Casey

More than 1 million women around the world are diagnosed with breast cancer each year, and receptor testing conducted on biopsied tissue typically finds that eight in 10 have estrogen receptor-positive breast cancer. Hormone receptor status can be valuable for classifying tumors and for guiding treatment, such as by identifying women who might benefit from endocrine therapy.

April 15, 2019